BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Authors » Brady Huggett

Articles by Brady Huggett

GenStar, Vascular Genetics To Form Autus, Combine Focuses

Sep. 16, 2002
By Brady Huggett
Vascular Genetics Inc. and GenStar Therapeutics Corp. are merging to form Autus Genetics Corp., a company that will focus on the lead products of both of its parts. The merger was born out of a conversation between the two heads of the companies early this year. (BioWorld Today)
Read More

GenStar, Vascular Genetics To Form Autus, Combine Focuses

Sep. 16, 2002
By Brady Huggett
Vascular Genetics Inc. and GenStar Therapeutics Corp. are merging to form Autus Genetics Corp., a company that will focus on the lead products of both of its parts. The merger was born out of a conversation between the two heads of the companies early this year. (BioWorld Today)
Read More

IDEC Views Early IDEC-114 Data In Psoriasis, Drops Indication

Sep. 6, 2002
By Brady Huggett

IDEC Views Early IDEC-114 Data In Psoriasis, Drops Indication

Sep. 6, 2002
By Brady Huggett

Aventis Declines Option For Alliance On Indevus' Pagoclone

Sep. 3, 2002
By Brady Huggett

Aventis Declines Option For Alliance On Indevus' Pagoclone

Sep. 3, 2002
By Brady Huggett

Alliance Cuts Staff, Pressures Venture For Oxygent Funding

Aug. 30, 2002
By Brady Huggett
Alliance Pharmaceutical Corp. has spent more than $200 million developing its intravascular oxygen carrier, Oxygent. But now facing a revised development plan that it cannot afford, Alliance cut 40 percent of its work force and warned PFC Therapeutics LLC, the joint venture set up to commercialize the product, that if funds don't materialize, the Oxygent license agreement will be terminated and the joint venture dissolved. (Bioworld Today)
Read More

Alliance Cuts Staff, Pressures Venture For Oxygent Funding

Aug. 30, 2002
By Brady Huggett
Alliance Pharmaceutical Corp. has spent more than $200 million developing its intravascular oxygen carrier, Oxygent. But now facing a revised development plan that it cannot afford, Alliance cut 40 percent of its work force and warned PFC Therapeutics LLC, the joint venture set up to commercialize the product, that if funds don't materialize, the Oxygent license agreement will be terminated and the joint venture dissolved. (Bioworld Today)
Read More

FDA-Requested Report Examines Animal Biotechnology Concerns

Aug. 26, 2002
By Brady Huggett
In a report that was requested by the FDA to better arm itself for the upcoming animal biotechnology regulatory decisions it will surely face, the National Academies' National Research Council said the gravest concern associated with the merging of biotechnology and animals is environmental. (BioWorld Today)
Read More

FDA-Requested Report Examines Animal Biotechnology Concerns

Aug. 26, 2002
By Brady Huggett
In a report that was requested by the FDA to better arm itself for the upcoming animal biotechnology regulatory decisions it will surely face, the National Academies' National Research Council said the gravest concern associated with the merging of biotechnology and animals is environmental. (BioWorld Today)
Read More
Previous 1 2 … 52 53 54 55 56 57 58 59 60 … 74 75 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing